Clinical trial
A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.
NCT01958957 is registered in ClinicalTrials.gov with Jiangsu Kanion Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.
- Lead sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2013
- Completion date
- October 31, 2014
- Enrollment
- 6,300 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.